Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Panos Kefalas

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of Market Access & Health Policy|October 4, 2016
A price comparison of recently launched proprietary pharmaceuticals in the UK and the USJesper Jørgensen, Panos Kefalas
Journal of Market Access & Health Policy|August 26, 2017
Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact testJesper Jørgensen, Panos Kefalas
Journal of Market Access & Health Policy|July 16, 2019
Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimateJesper Jørgensen, Panos Kefalas
Journal of Market Access & Health Policy|April 29, 2016
Reimbursement of licensed cell and gene therapies across the major European healthcare marketsJesper Jørgensen, Panos Kefalas
Regenerative Medicine|April 13, 2021
The use of innovative payment mechanisms for gene therapies in Europe and the USAJesper Jørgensen, Panos Kefalas
Journal of Pharmaceutical Sciences|September 12, 2020
Clinical Adoption of Advanced Therapies: Challenges and OpportunitiesMichaela Sharpe, Jacqueline Barry, Panos Kefalas
Journal of Market Access & Health Policy|February 19, 2019
Data collection infrastructure for patient outcomes in the UK - opportunities and challenges for cell and gene therapies launchingJesper Jørgensen, Laura Mungapen, Panos Kefalas
Journal of Market Access & Health Policy|February 22, 2020
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countriesJesper Jørgensen, Eve Hanna, Panos Kefalas
Regenerative Medicine|July 11, 2022
Using analogue data to substantiate long-term durability of gene therapies: a narrative reviewMichaela Sharpe, Laura Beswick, Panos Kefalas
Journal of Market Access & Health Policy|October 27, 2018
The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's diseaseJesper Jørgensen, Spiros Servos, Panos Kefalas
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Market Access & Health Policy|October 4, 2016
A price comparison of recently launched proprietary pharmaceuticals in the UK and the USJesper Jørgensen, Panos Kefalas
Journal of Market Access & Health Policy|August 26, 2017
Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact testJesper Jørgensen, Panos Kefalas
Journal of Market Access & Health Policy|July 16, 2019
Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimateJesper Jørgensen, Panos Kefalas
Journal of Market Access & Health Policy|April 29, 2016
Reimbursement of licensed cell and gene therapies across the major European healthcare marketsJesper Jørgensen, Panos Kefalas
Regenerative Medicine|April 13, 2021
The use of innovative payment mechanisms for gene therapies in Europe and the USAJesper Jørgensen, Panos Kefalas
Journal of Pharmaceutical Sciences|September 12, 2020
Clinical Adoption of Advanced Therapies: Challenges and OpportunitiesMichaela Sharpe, Jacqueline Barry, Panos Kefalas
Journal of Market Access & Health Policy|February 19, 2019
Data collection infrastructure for patient outcomes in the UK - opportunities and challenges for cell and gene therapies launchingJesper Jørgensen, Laura Mungapen, Panos Kefalas
Journal of Market Access & Health Policy|February 22, 2020
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countriesJesper Jørgensen, Eve Hanna, Panos Kefalas
Regenerative Medicine|July 11, 2022
Using analogue data to substantiate long-term durability of gene therapies: a narrative reviewMichaela Sharpe, Laura Beswick, Panos Kefalas
Journal of Market Access & Health Policy|October 27, 2018
The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's diseaseJesper Jørgensen, Spiros Servos, Panos Kefalas
Pageof 2